NYLIM
RNAM

New York Life Investment Management’s Avidity Biosciences RNAM Stock Holding History

New York Life Investment Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-62,920
Closed -$4.54M – 815
2025
Q4 		$4.54M Buy
+62,920
New +$4.06M 0.04% 338
2023
Q1 		– Sell
-30,713
Closed -$682K – 1355
2022
Q4 		$682K Buy
30,713
+3,295
+12% +$49.1K 0.01% 695
2022
Q3 		$448K Buy
27,418
+2,170
+9% +$41.5K 0.01% 836
2022
Q2 		$367K Buy
+25,248
New +$376K ﹤0.01% 1058

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $206M AUM 26.42% 1-Year Est. Return

New York Life Investment Management's RNAM Position: Q1 2026 in Review

New York Life Investment Management sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 62,920 shares — an estimated $4.54M sold.

New York Life Investment Management first reported a position in RNAM in Q2 2022 and held it in 4 quarters. The position peaked at $4.54M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • New York Life Investment Management reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • New York Life Investment Management sold 62,920 Avidity Biosciences shares in Q1 2026, an estimated $4.54M.
  • New York Life Investment Management first reported a position in Avidity Biosciences in Q2 2022 and held it in 4 quarters.
  • New York Life Investment Management's Avidity Biosciences position peaked at $4.54M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on New York Life Investment Management's 13F filing for Q1 2026, filed 7 May 2026.